KHKristina K. Hardy

Kristina K. Hardy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristina K. Hardy has a total of 269 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Remote assessment of neurocognition: knowledge gaps and opportunities for research

    by Kristina K Hardy, Richard Benson, Janna M Belser-Ehrlich, Nicole Y Farhat, Lina Garcia, Rebecca E Hommer, Tracy M King, May E Montasser, Anna E Ordóñez, Holly L Storkel, et al.

  • Reply to C.T. Matava et al

    by Sarah Alexander, John A. Kairalla, Sumit Gupta, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J. Winick, Kevin R. Krull, Wanda L. Salzer, Michael J. Burke, et al.


  • Open Access

    Attention and executive functioning in children and adolescents treated for high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG)

    by Kristina K. Hardy, Leanne Embry, John A. Kairalla, Christina Sharkey, Anthony R. Gioia, Danielle Griffin, Carly Berger, Hannah S. Weisman, Robert B. Noll, Naomi J. Winick

    Objectives: Survivors of childhood B‐acute lymphoblastic leukemia (B‐ALL) are at risk for difficulties with attention and executive functioning (EF) as a late effect of treatment. The present study aimed to identify treatment and demographic factors associated with risk for difficulties with EF in youth treated for high‐risk B‐ALL.Method: Children and adolescents with B‐ALL treated on Children's Oncology Group (COG) protocol AALL0232 were randomized to high‐dose or escalating‐dose methotrexate (MTX), and either dexamethasone or prednisone during the induction phase. Neuropsychological functioning was evaluated via protocol AALL06N1, including performance‐based and parent‐report measures, for 177 participants (57% female, 81% white; mean age at diagnosis = 8.4 years; SD = 5.0) 8‐24 months following treatment completion.Results: Mean scores for all attention and EF measures were within the average range, with no significant differences as a function of MTX delivery or steroid treatment (all p > 0.05). In multivariable models, participants with US public insurance exhibited significantly greater parent‐reported EF difficulties than those with US private or non‐US insurance (p ≤ 0.05). Additionally, participants diagnosed under 10 years of age performed significantly more poorly on measures of attention (i.e., continuous performance task, p ≤ 0.05) and EF (i.e., verbal fluency and tower planning task, p ≤ 0.05).Conclusions: For survivors of pediatric B‐ALL, treatment‐related factors were not associated with attention or EF outcomes. In contrast, outcomes varied by demographic characteristics, including age and insurance type, an indicator of economic hardship. Future research is needed to more directly assess the contribution of socioeconomic status on cognitive outcomes in survivors.


  • Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study

    by Sarah Alexander, John A. Kairalla, Sumit Gupta, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J. Winick, Kevin R. Krull, Wanda L. Salzer, Michael J. Burke, et al.

    PURPOSE: Many children treated for ALL develop long-term neurocognitive impairments. Increased risk of these impairments is associated with treatment and demographic factors. Exposure to anesthesia is an additional possible risk factor. This study evaluated the impact of cumulative exposure to anesthesia on neurocognitive outcomes among a multicenter cohort of children with ALL. METHODS: This study was embedded in AALL1131, a Children's Oncology Group phase III trial for patients with high-risk B-ALL. In consenting patients age 6-12 years, prospective uniform assessments of neurocognitive function were performed during and at 1 year after completion of therapy. Exposure to all episodes of anesthetic agents was abstracted. Multivariable linear regression models determined associations of cumulative anesthetic agents with the primary neurocognitive outcome reaction time/processing speed (age-normed) at 1 year off therapy, adjusting for baseline neurocognitive score, age, sex, race/ethnicity, insurance status (as a proxy for socioeconomic status), and leukemia risk group. RESULTS: One hundred and forty-four children, 76 (52.8%) males, mean age of 9.1 (min-max, 6.0-12.0) years at diagnosis, underwent a median of 27 anesthetic episodes (min-max, 1-37). Almost all patients were exposed to propofol (140/144, 97.2%), with a mean cumulative dose of 112.3 mg/kg. One year after therapy, the proportion of children with impairment ( Z-score ≤–1.5) was significantly higher compared with a normative sample. In covariate-adjusted multivariable analysis, cumulative exposure to propofol was associated with a 0.05 Z-score decrease in reaction time/processing speed per each 10 mg/kg propofol exposure ( P = .03). CONCLUSION: In a multicenter and uniformly treated cohort of children with B-ALL, cumulative exposure to propofol was an independent risk factor for impairment in reaction time/processing speed 1 year after therapy. Anesthesia exposure is a modifiable risk, and opportunities to minimize propofol use should be considered.


  • Impaired neurocognitive functioning 3 months following diagnosis of high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group

    by Kristina K. Hardy, John A. Kairalla, Anthony R. Gioia, Hannah S. Weisman, Meera Gurung, Robert B. Noll, Pamela S. Hinds, Emily Hibbitts, Wanda L. Salzer, Michael J. Burke, et al.

    Purpose: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer diagnosis. Cognitive late effects develop in 20%–40% of ALL survivors, but the course of declines is unclear. The aim of this paper is to characterize cognitive functioning, and its association with patient‐reported outcomes, early in treatment.Patients and methods: A total of 483 children with high‐risk ALL, aged 6–12 years at diagnosis, consented to the neurocognitive study embedded in a prospective therapeutic trial, Children's Oncology Group (COG) AALL1131. A computerized neurocognitive battery (Cogstate) was administered 3 months post diagnosis assessing reaction time, visual attention, working memory, visual learning, and executive functioning. Parent‐reported executive functioning and patient‐reported physical symptoms were also collected.Results: Data from 390 participants (mean age at diagnosis = 9.2 years, 55.4% male) were obtained. Relatively few patients reported pain (16.0%) or nausea (22.6%), but a majority (68.5%) reported feeling at least some fatigue at testing. Mean Cogstate Z‐scores were within normal limits across tasks; however, rates of impairment (Z‐scores ≤ −1.5) for reaction time, working memory, visual learning, and visual attention were all higher than expected compared to the standardization sample. Patients reporting fatigue were significantly more likely to have impaired reaction time and visual attention compared to those reporting no fatigue.Conclusion: Findings support feasibility of computerized cognitive assessments and suggest higher‐than‐expected rates of impaired cognitive performance early during treatment for pediatric ALL, notably within 3 months of diagnosis, suggesting intervention efforts may be indicated. These results also highlight acute factors that may impact reliability of “baseline” assessments conducted soon after diagnosis.


  • Leukemia and sickle cell disease.

    by Kristina K. Hardy, Christina M. Sharkey, Hannah Weisman, Steven J. Hardy

  • Computerized Working Memory Training for Children With Neurofibromatosis Type 1 (NF1): A Pilot Study

    by Kristina K. Hardy, Carly Berger, Danielle Griffin, Karin S. Walsh, Christina M. Sharkey, Hannah Weisman, Anthony Gioia, Roger J. Packer, Maria T. Acosta

    The present study aimed to evaluate the feasibility and efficacy of CogmedRM, a computerized, home-based working memory (WM) training program, in children with NF1. A pre-post design was used to evaluate changes in performance-based measures of attention and WM, and parent-completed ratings of executive functioning. Children meeting eligibility criteria completed CogmedRM over 9 weeks. Primary outcomes included compliance statistics and change in attention and WM scores. Thirty-one children (52% male; M age = 10.97 ± 2.51), aged 8-15, were screened for participation; 27 children (87%) evidenced WM difficulties and participated in CogmedRM training. On average, participants completed 19.7 out of 25 prescribed sessions, with an adherence rate of 69%. Participants demonstrated improvements in short-term memory, attention, and executive functioning (all Ps < .05). Results suggest that computerized, home-based WM training programs may be both feasible and efficacious for children with NF1 and cognitive deficits.


  • Open Access

    Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1

    by Jennifer A. Janusz, Bonita P. Klein-Tasman, Jonathan M. Payne, Pamela L. Wolters, Heather L. Thompson, Staci Martin, Peter de Blank, Nicole Ullrich, Allison del Castillo, Maureen Hussey, et al.

    Objective To review parent-report social skills measures to identify and recommend consensus outcomes for use in clinical trials of social deficit in children and adolescents (ages 6–18 years) with neurofibromatosis type 1 (NF1). Methods Searches were conducted via PubMed and ClinicalTrials.gov to identity social skills outcome measures with English language versions used in clinical trials in the past 5 years with populations with known social skills deficits, including attention-deficit/hyperactivity disorder and autism spectrum disorder (ASD). Measures were rated by the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) Neurocognitive Committee on patient characteristics, use in published studies, domains assessed, availability of standard scores, psychometric properties, and feasibility to determine their appropriateness for use in NF1 clinical trials. Results Two measures were ultimately recommended by the committee: the Social Responsiveness Scale–2 (SRS-2) and the Social Skills Improvement System–Rating Scale (SSIS-RS). Conclusions Each of the 2 measures assesses different aspects of social functioning. The SSIS-RS is appropriate for studies focused on broader social functioning; the SRS-2 is best for studies targeting problematic social behaviors associated with ASD. Researchers will need to consider the goals of their study when choosing a measure, and specific recommendations for their use are provided.


  • Top Cited Papers

    Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma

    by Jeff M. Michalski, Anna J. Janss, L. Gilbert Vezina, Kyle S. Smith, Catherine A. Billups, Peter C. Burger, Leanne M. Embry, Patricia L. Cullen, Kristina K. Hardy, Scott L. Pomeroy, et al.

    PURPOSE: Children with average-risk medulloblastoma (MB) experience survival rates of ≥ 80% at the expense of adverse consequences of treatment. Efforts to mitigate these effects include deintensification of craniospinal irradiation (CSI) dose and volume. METHODS: ACNS0331 (ClinicalTrials.gov identifier: NCT00085735 ) randomly assigned patients age 3-21 years with average-risk MB to receive posterior fossa radiation therapy (PFRT) or involved field radiation therapy (IFRT) following CSI. Young children (3-7 years) were also randomly assigned to receive standard-dose CSI (SDCSI; 23.4 Gy) or low-dose CSI (LDCSI; 18 Gy). Post hoc molecular classification and mutational analysis contextualized outcomes according to known biologic subgroups (Wingless, Sonic Hedgehog, group 3, and group 4) and genetic biomarkers. Neurocognitive changes and ototoxicity were monitored over time. RESULTS: Five hundred forty-nine patients were enrolled on study, of which 464 were eligible and evaluable to compare PFRT versus IFRT and 226 for SDCSI versus LDCSI. The five-year event-free survival (EFS) was 82.5% (95% CI, 77.2 to 87.8) and 80.5% (95% CI, 75.2 to 85.8) for the IFRT and PFRT regimens, respectively, and 71.4% (95% CI, 62.8 to 80) and 82.9% (95% CI, 75.6 to 90.2) for the LDCSI and SDCSI regimens, respectively. IFRT was not inferior to PFRT (hazard ratio, 0.97; 94% upper CI, 1.32). LDCSI was inferior to SDCSI (hazard ratio, 1.67%; 80% upper CI, 2.10). Improved EFS was observed in patients with Sonic Hedgehog MB who were randomly assigned to the IFRT arm ( P = .018). Patients with group 4 MB receiving LDCSI exhibited inferior EFS ( P = .047). Children receiving SDCSI exhibited greater late declines in IQ (estimate = 5.87; P = .021). CONCLUSION: Reducing the radiation boost volume in average-risk MB is safe and does not compromise survival. Reducing CSI dose in young children with average-risk MB results in inferior outcomes, possibly in a subgroup-dependent manner, but is associated with better neurocognitive outcome. Molecularly informed patient selection warrants further exploration for children with MB to be considered for late-effect sparing approaches.